Investment Rating - The investment rating for the company is maintained as "Buy" [2][7]. Core Insights - The company is expanding its medical and elderly care business, enhancing multi-business synergy, which is expected to drive future growth [6]. - The higher education segment is experiencing stable growth, with a projected increase in student enrollment and tuition fees over the next three years [5][7]. - The medical and elderly care business has shown significant growth potential, with revenue expected to reach 170 million yuan by 2027, reflecting a compound annual growth rate of 40.8% [6][7]. Financial Data and Profit Forecast - The company's revenue is projected to grow from 1,806 million yuan in 2023 to 2,376 million yuan in 2027, with a compound annual growth rate of approximately 6.62% [8]. - The adjusted net profit is expected to decline from 429 million yuan in 2023 to 389 million yuan in 2025, before recovering to 477 million yuan by 2027 [11]. - Earnings per share are forecasted to decrease from 0.66 yuan in 2023 to 0.60 yuan in 2025, with a slight recovery to 0.73 yuan by 2027 [8].
东软睿新集团（09616）：开拓医养业务，提升多业务协同效应，未来增长可期